Abcellera Biologics Inc ABCL

$12.70 +0.05 (0.40%)

Valuation

Market cap
3,893,960,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,383,800
Avg volume
6,838,356
Day's range
$12.29 – $12.93
Shares out
306,611,000
Stochastic %K
79%
Beta
1.32
Analysts
Strong Sell
Price target
$16.67

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stocktradesmoon Sep 28, 7:19 AM
$ABCL $ABCL SOON
0 replies
Stocktradesmoon Sep 28, 5:40 AM
$ABCL $ABCL is going to make millionaires soon
0 replies
erpy Sep 28, 2:01 AM
$ABCL Lets GO
0 replies
Bastox Sep 28, 1:41 AM
$ABCL More on Jones: Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABCL in relation to earlier this year. Last month, John S. Montalbano, a Director at ABCL bought 10,000.00 shares for a total of $110,300.00.
0 replies
Bastox Sep 28, 1:39 AM
$ABCL Jones Trading reiterates buy on ABCL $25 price target JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on AbCellera Biologics today and set a price target of $25.00.
0 replies
Stocktradesmoon Sep 27, 11:15 PM
$ABCL 👀📈👏👏👏👏 $ABCL @AbCelleraBio AbCellera in a "high and tight flag" pattern, one of the most bullish technical setups that exists. If 12 week data comes out positive see you abcellerites at $20+ 💣
0 replies
Bastox Sep 27, 10:31 PM
$ABCL Gotta give StockMoon his props That Abbvie news may be true!
0 replies
Stocktradesmoon Sep 27, 8:41 PM
$ABCL October 1st is not just another date on the calendar. ABCL635 Phase 2 data will be presented at the IMS World Congress on Menopause. We already know the topline results were positive. Now we get to see more of the actual data. For me, this is exactly why I own $ABCL Not for tomorrow. Not for a quick trade. Not because I expect every catalyst to send the stock +20%. I own it because if AbCellera proves it can repeatedly take internally developed antibodies from discovery to meaningful clinical assets, the entire way the market values this company can change. ABCL635 is one test of that thesis. October 1st matters. 👀 But the story is much BIGGER than October 1st. I’m holding. Let’s see the data.
0 replies